New hope for tough brain tumors: drug trial targets recurrent meningioma
NCT ID NCT07428616
First seen Feb 26, 2026 · Last updated May 15, 2026 · Updated 8 times
Summary
This study tests a drug called zanzalintinib in 100 people with meningioma (a type of brain tumor) that has returned or grown despite standard treatments like surgery or radiation. The goal is to see if the drug can shrink tumors or slow their growth. Participants take the drug by mouth, and the study will monitor tumor response and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MENINGIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.